Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN9933, REGN7508, and REGN9533 in End-Stage Kidney Disease on Hemodialysis
NCT07759167Phase 1Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in end-stage kidney disease (ESKD) comparing REGN9933 + Heparin, REGN7508 + Heparin and REGN9533 + Heparin (3 arms). Primary endpoints: Occurrence of Treatment-Emergent Adverse Events (TEAEs) at 78 days and Severity of TEAEs at 78 days. Started Sep 2026; status: recruiting.
02
Drugs
amrecibartcenvacibartREGN9533
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NCT07759167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07759167.